Optimizing the human perinatal progenitor cell secretome for future paracrine therapy to counteract cardiac disease with AmnioSMART: an ERA4Health-funded project

The EU-funded Partnership ‘Fostering a European Research Area for Health’ (ERA4Health) is a programme bringing together 33 institutions from different countries, including 17 out of the 27 members of the EU, and 5 Third Countries (from which 3 are associated to Horizon Europe). The main aim of the ERA4health is to regularly sponsor international joint calls for proposals aimed at developing breakthrough collaborative research joint strategies to address current unmet clinical needs and thus reduce disease burden across Europe (source: https:// era4health.eu/at-a-glance). Among the different funding opportunities, the 2023 ERA4Health framework focused on innovative, yet feasible, treatments for cardiovascular disease with specific translational potential, as per the main goal of the call: ‘Research targeting development of innovative therapeutic strategies in cardiovascular disease (CARDINNOV)’.